CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-11 | Young Wendy B. Director | Purchase | +3,500 | $22.60 | $79K | 9,500 |
| 2025-09-08 | Gault Cheryl Chief Operating Officer | Option exercise 10b5-1 | +5,000 | $1.80 | $9K | 176,928 |
| 2025-09-08 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −5,000 | $38.33 | $192K | 171,928 |
| 2025-09-08 | Gault Cheryl Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 110,407 | ||
| 2025-08-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,300 | $14.98 | $124K | 426,842 |
| 2025-08-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −200 | $15.79 | $3K | 426,642 |
| 2025-07-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,500 | $14.00 | $119K | 435,142 |
| 2025-06-17 | Sanchez Ramiro Director | Grant or award · Stock Option (Right to Buy) | +10,925 | 10,925 | ||
| 2025-06-17 | Young Wendy B. Director | Grant or award · Stock Option (Right to Buy) | +10,925 | 10,925 | ||
| 2025-06-17 | MARAGANORE JOHN Director | Grant or award · Stock Option (Right to Buy) | +21,850 | 21,850 | ||
| 2025-06-17 | HEALY JAMES Director | Grant or award · Stock Option (Right to Buy) | +21,850 | 21,850 | ||
| 2025-06-17 | PEREZ ROBERT J Director | Grant or award · Stock Option (Right to Buy) | +10,925 | 10,925 | ||
| 2025-06-17 | Huber Reid M Director | Grant or award · Stock Option (Right to Buy) | +21,850 | 21,850 | ||
| 2025-06-17 | PAUL STEVEN M Director | Grant or award · Stock Option (Right to Buy) | +21,850 | 21,850 | ||
| 2025-06-17 | Silva Paul M Director | Grant or award · Stock Option (Right to Buy) | +10,925 | 10,925 | ||
| 2025-06-16 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,500 | $11.00 | $94K | 443,642 |
| 2025-05-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,500 | $9.56 | $81K | 452,142 |
| 2025-04-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,500 | $9.57 | $81K | 460,642 |
| 2025-04-01 | Sevigny Jeffrey Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2025-03-14 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,500 | $10.85 | $92K | 469,142 |
Page 7 of 10 · 186 trades